Who Owns the Formula? IP, Exclusivity and Contracts in Supplement Manufacturing

Why brand owners ask this question too late

The question usually lands after the sample has been approved and the deposit is being discussed: if I pay for this, do I own the formula? By then the answer has already been written into three documents, and none of them is the one the brand read most carefully. The sample proves the product works. It says nothing about who is allowed to make the formula.

Supplement formula ownership is decided by the development agreement and the supply agreement attached to it, not by the sample, the invoice or the handshake. Paying for development buys a service, and in most jurisdictions the party that creates a work owns it until that ownership is assigned in writing. That one sentence explains how a brand can spend five figures developing a formula and still be unable to stop the factory from filling it into another customer's pouch.

This guide is for brand owners who are about to commission something custom and want the ownership question settled before the purchase order rather than after the first lookalike appears. It walks through the three development routes, which parts of a formula are genuinely protectable and which are commodity, the five documents that decide the answer, what exclusivity really costs, and the transfer package to negotiate while everyone is still friendly.

Two earlier guides frame the decision on formula ownership: private label versus custom at ingredient level explains what you are actually buying in each route, and brief, samples and spec freeze shows where the paperwork belongs in the calendar.

Three routes to a formula, and only one of them is automatic

Every project falls into one of three routes, and the route sets the default answer before a single clause is negotiated. The first is a stock or catalogue formula: the factory already runs it, has validated it, holds the stability data and sells it to anyone who meets the minimum. In that route the factory owns the formula and you are buying a licence to put your label on it. This is private label in its strict sense, and it is the fastest route to market for a reason.

The second route is a custom formula the brand commissions and pays for. Here the default is far less generous than most buyers assume. Development work produces intellectual property, and unless the development agreement assigns that property to the brand, it stays with whoever created it. A payment for services is not a transfer of rights. If the agreement is silent on assignment, expect a dispute rather than a handshake.

The third route produces the worst outcomes: a jointly developed formula, where the factory's existing base is modified at the brand's request. Two parties have contributed, and the result is a shared asset that neither can cleanly license or move. The fix is boring but decisive, and it costs one paragraph in the agreement. Name the background intellectual property each party brings, name the foreground intellectual property the project creates, and assign the foreground property to one named owner.

The row that surprises people is the third one. A factory that waives the development fee is not doing a favour; it is keeping the asset and recovering the cost in unit price over the next three orders. Waived development is the clearest market signal in this industry that you do not own the formula, and it is worth asking about directly.

What in a supplement formula is actually protectable

The uncomfortable answer is that most of it is not. A single-ingredient product is a commodity purchase with a label on it. Creatine monohydrate at five grams a serving is defined by a pharmacopeial monograph: the purity, the particle size and the loss on drying are all specified before anyone gets involved. Any competent factory can fill it, and exclusivity on such a product is a promise about behaviour rather than a property right. This is why supplement formula ownership matters far less on a commodity SKU than on a differentiated one.

What is protectable in a formula sits in four layers, and the top two are the ones worth negotiating hard. The first is the ingredient combination and the ratio in the formula, which is a trade secret for as long as it stays secret. The second is the specification detail behind the formula: the marker the extract is standardised to, the mesh the powder is milled to, the overage applied to a vitamin that degrades. The third is the flavour and masking system, which is the hardest layer for a competitor to reverse engineer and the one most supply agreements never mention. The fourth is the process itself.

• The ratio: a twelve-ingredient formula at a specific ratio is a recipe, and a recipe is a trade secret while you keep it secret.
• The specification: the marker compound, the mesh size and the overage are what make two formulas with the same ingredient list behave differently.
• The flavour system: masking a bitter botanical or a sulphur note is real bench work, and it is the layer a competitor cannot read off a label.
• The process: blend time and compression force change hardness, dissolution and fill weight for an identical ingredient list.
• The claims and the artwork: not part of the formula at all, but the assets that buyers confuse with it most often.

The practical consequence is straightforward. If your product is a single commodity ingredient, spend the money on trademark, artwork and speed rather than on exclusivity clauses over the formula, because the clause would be protecting something nobody can own. If your product is a differentiated formula or a difficult flavour, spend it on the assignment language and on process controls, because that is where the value actually sits.

Patents versus trade secrets: the economics are not close

Brand owners occasionally ask whether the formula should be patented. For a dietary supplement it almost never should be. A patent application publishes at eighteen months, which hands the formula to every competitor in the market in exchange for protection that is expensive to obtain and harder to enforce than it looks. A US utility patent commonly runs five figures in filing and prosecution costs alone, and a supplement formula struggles to clear the novelty bar when dozens of similar products are already on the shelf.

The trade secret route is cheaper and, in this industry, stronger. A trade secret costs nothing to register, lasts for as long as the secrecy holds, and covers exactly the things a patent cannot: a masking system, a mill setting, a supplier-specific grade of raw material. The trade-off is absolute. The moment the formula is published, in a patent, in a public filing or in a marketing deck sent to a retailer, the protection ends. That is why the confidentiality clause is worth more than the patent budget.

The five documents that decide supplement formula ownership

Five documents decide who owns the formula, and usually only two of them get signed. None is long, reading them takes an afternoon, and skipping them is the most expensive shortcut available in this industry.

The last row catches people who thought they had finished. A label design created by a factory employee belongs to that employee's employer unless it is assigned, and product photography belongs to whoever pressed the shutter. If your launch depends on a photo set you cannot prove a licence to, you are renting your own brand's shelf presence.

One clause deserves a paragraph of its own, because it decides whether the protection survives a bad year: change control. A formula that the factory can alter without your written approval is a formula you do not control, regardless of who owns it on paper. Require written approval for any change to an ingredient supplier, a specification limit or a process parameter, and require the factory to requote rather than silently substitute when a material becomes unavailable.

What exclusivity actually costs, and what breaks it

Exclusivity is not a favour and it is not free. It is a priced option on a factory's capacity, and the price is paid in one of three currencies: a premium on unit price, a committed annual volume, or a development fee paid up front. A factory that grants free exclusivity to anyone who asks has granted it to nobody, because it has no mechanism to enforce a promise made without consideration.

The chart is illustrative rather than a quotation, but the shape reflects how these deals are built. The narrower the scope, the cheaper it is, and the option with no volume floor is the most expensive because it moves all the risk onto the factory. What matters more than the number is the currency, because each one fails in a different way.

There is one exclusivity request that no serious factory will sign, and asking for it signals inexperience: perpetual, worldwide, all-channel exclusivity on a formula the factory developed, with no volume commitment attached. It is an open-ended transfer of an asset in exchange for nothing. The requests that get signed are the ones where the brand takes measurable risk in return, whether that is a committed annual volume, a paid development fee, or a tooling investment the factory could not otherwise recover.

How a factory keeps one brand's formula out of another's

A factory running four competing products in the same category owes a duty to all four, and the mechanism is less glamorous than a legal clause. It is internal process, and a brand can audit it in ten minutes by asking how the bill of materials is stored. A factory that emails an unmodified spreadsheet to whoever asks is telling you exactly how it treats every customer's formula.

1. The bill of materials is issued with coded ingredient names, and the decoding key is held by one or two named people rather than by the whole sales team.
2. Production sees a works order with weights and parameters, not a marketing specification with actives and ratios spelled out.
3. Raw material purchasing is split, so that no single buyer can reconstruct a formula from purchase orders alone.
4. Samples of competing formulations are stored separately, labelled by customer code rather than by product name.
5. Line changeovers include a documented cleaning and clearance step, and that record is retained with the batch record.
6. Photography and video on a line running a confidential formula is restricted, because a ten-second clip can reveal a pack format and a piece count.

The flavour point deserves emphasis because it is the least protected layer in the industry. Six variants of the same collagen base formula look identical on a label: the same five thousand milligrams, the same vitamin C, the same servings per pouch. What differs is the masking system that makes a hydrolysed collagen palatable in water, and that system represents hundreds of hours of bench work no competitor can copy from a panel. If you funded it, it belongs in the assignment clause by name.

If the relationship ends: the transfer package to negotiate now

The moment to negotiate a second source for the formula is before the first order, when everyone is optimistic and the factory has every reason to agree. Once volumes are running, the leverage reverses. What follows is the package worth asking for, and it is the same package a new factory will ask you for, so building it early costs nothing and saves eight to fourteen weeks later.

1. The full bill of materials with ingredient grades, not just names, including the specification each material has to meet.
2. The manufacturing specification: target weights, tolerances, blend time, screen size, compression force or fill temperature as applicable.
3. The approved finished product specification with test methods and limits, which is the document a new factory will be audited against.
4. The flavour system reference, or a written commitment that the flavour house will supply the same compound to a named alternative.
5. Tooling drawings for any custom tablet punch, mould or bottle, plus written confirmation of who paid for them and who may collect them.
6. Artwork source files in an editable format rather than flattened print-ready files, plus a written assignment or perpetual licence.
7. The stability protocol and any data already generated, because a new factory will not inherit the shelf life claim without it.
8. One retained production sample per lot, or a written commitment that the factory will release samples to you on request.
9. A named technical contact after the final invoice, with a response time written into the agreement rather than into an email.
10. The right to audit how the formula is protected, or at minimum a written description of the controls in place.

The item that causes the most arguments is tooling. Custom tablet punches and gummy moulds cost real money, typically somewhere between one and four thousand US dollars per station set, and factories reasonably refuse to release tooling to a customer who still owes them money. The clean answer is to settle tooling ownership and collection rights in the development agreement, with the final invoice as the trigger, rather than discovering the disagreement on the day you want to move.

Trademark, artwork and photography are separate assets

A brand name is not part of the formula and is protected by an entirely different mechanism. Register the trademark in your own name in the markets you sell into, and do it before the first shipment rather than after the first distributor asks for proof. A factory that offers to register it for you should be refused: a trademark held by your supplier is a lever against you, and unwinding one costs far more than the registration ever did.

Trade dress, which covers the overall look of the pack, is the second layer and the one that actually deters copycats on a marketplace, because a platform will act on a look and feel complaint far faster than on a recipe dispute. The third layer is the label copyright and the photography licence. Both are works created by someone, both default to the creator, and both need a written assignment or a licence that permits commercial reuse.

The physical pack is where all three layers meet, which is why the packaging guide covers artwork ownership alongside structure and materials. For the formula itself, the creatine monohydrate program is the commodity end of the range and the multi collagen capsule program is the differentiated end, and the ownership question is different for each.

Related reading: MOQ and lead times explains why a small first order weakens an exclusivity ask, quality control and batch release covers the change control clause in practice, and line extensions shows how one base formula becomes a range you can defend.

Where this leaves the negotiation

None of this is adversarial, and a factory that reacts badly to these questions is answering them. The questions are normal: who owns the formula we are about to develop, what happens to it if we stop buying, and what happens to it if you sell the same thing to our competitor. A capable partner has the answers in writing, because it has had this conversation before and built the paperwork for it.

The brands that get hurt are not the ones who asked too many questions. They are the ones who approved a sample, paid a deposit, and discovered eighteen months later that the formula they funded is now listed by a competitor with the same specification and a better price. Supplement formula ownership is one clause, it costs an afternoon to settle, and it is the difference between owning a product and renting one.